Thyrotropin-releasing hormone in schizophrenia.
Oral administration of thyrotropin-releasing hormone (TRH) caused deterioration in the clinical status of seven out of nine schizophrenic men. This change was particularly apparent in the four patients diagnosed as paranoid schizophrenics. Such changes might be expected from a drug with properties similar to amphetamine.
D000284:Administration, Oral; D000328:Adult; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D012075:Remission, Spontaneous; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy*; D012563:Schizophrenia, Paranoid / Q000188:drug therapy; D012565:Schizophrenic Psychology; D012737:Sex Factors; D013973:Thyrotropin-Releasing Hormone / Q000008:administration & dosage / Q000627:therapeutic use*
D013973:Thyrotropin-Releasing Hormone